Arguments en faveur du traitement précoce de la maladie de Parkinson par les agonistes dopaminergiques;Arguments en faveur du traitement précoce de la maladie de Parkinson par les agonistes dopaminergiques

Revue Neurologique

Volumn 155, Issue 1, 1999, Pages 35-42

  Rascol, O ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; MENTAL DISEASE; PARKINSON DISEASE; REVIEW; TIME; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; HUMANS; LEVODOPA; MENTAL DISORDERS; PARKINSON DISEASE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032616796     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. ADLER C.H., SETHI K.D., HAUSER R.A., DAVIS T.L., HAMMERST AD J.P., BERTONI J., TAYLOR R.L, SANCHEZ-RAMOS J., O'BREN CF, for the Ropinirole Study Group (1997). Ropinirole for the treatment of early Parkinson's Disease. Neurology, 49:393-399.
2. AGIO Y., JAVOY-AGID F., RUBERG M. (1987). Biochemistry of neurotransmitters in Parkinson's disease. In Movement Disorders 2, Marsden CD and Fahn S (eds). Butterworths London, pp 166-230.
3. BEDARD P.J., Di PAOLOT., FALARDEAU P., BOUCHER R. (1986). Chronic treatment with levodopa, but not bromocriptine, induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with 3H-spiperone binding. Brain Res 379: 294-299.
4. BEDARD P.J., GOMEZ-MANCILLA B., BLANCHET P., CALON F., GRONDIN R., GAGNON C., FALARDEAU P., GOULET M., MORISSETTE M., ROUILLARD C., Di PAOLO T. (1997). Dopamine agonists as first line therapy of parkinsonism in MPTP monkeys. In : "Beyong the decade of the brain, vol 2, dopamine agonists in early Parkinson's disease", ed : Olanow W, Obeso J Wells Medical Limited, Royal Tunbridge Wells, pp 101-113.
5. BLANCHET P., BEDARD J.P., BRITTON D.R., KERABIAN J.W. (1993). Differential effect of selective D1 and D2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyI-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys. J Pharmacol Exp Ther, 267:275-279.
6. BOISSEL J.P., COLLET J.P., DUPUY C. (1996). Médecine factuelle ou comment accomplir une nécessaire et profonde évolution dans la pratique médicale. Thérapie, 51 : 207-208.
7. BORDET R., RlDRAY S., CARBONI S., DlAZ J., SOKOLOFF P., SCHWARTZ U.C. (1997). Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sei USA, 94:3363-3367.
8. BOSSARD N., BOISSEL J.P., DURU G. (1996). La hiérarchisation selon leur niveau de preuve des données sources, avant leur intégration dans une synthèse, en matière d'efficacité thérapeutique. Thérapie, 51:261-264.
9. BOYCE S., RUPNIAK N.M.J., STEVENTON M.J., IVERSEN S.D. (1990). Nigrostriatal damage is required for induction of dyskinesias by L-dopa in squirrel monkeys. Clinical Neuropharmacol, 13: 448-458.
10. CEDARBAUM J.M., GANDY S.E., MCDOWELL F.H. (1991). "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology, 41:622-629.
11. EVIDENCE-BASED MEDICINE WORKING GROUP (1992). Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA, 268 : 2420-2425.
12. FACTOR S.A., WEINER W.J., (1993). Viewpoint : early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disorders, 8 : 257-262.
13. FAHN S. (1996). Controversies in the therapy of Parkinson's disease. In : Adv Neural vol 69. L Battistin, G Scarlata, T Caraceni and S Ruggieri editors. Lippincott-Raven Publishers, Philadelphia, pp 477-486.
14. FAHN S., BRESSMAN S.B. (1984). Should levodopa therapy for parkinsonism be started early or late. Evidence against early treatment. Can J Neurol Sei, 11:200-206.
15. GOLBE L.I., LlEBERMAN A.N., MUENTER M.D., AHLSKOG J.E., GOPINATHAN G., NEOPHYTIDES A.N., Foo S.H., DUVOISIN R.C. (1988). Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol, 11:45-55.
16. GOULET M., MORISSETTE M., CALON F., BLANCHET P.J., FALARDEAU P., BEDARD P.J., Di PAOLO T. (1997). Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356 A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis. Neuroscience, 79:497-507.
17. HELY M.A., MORRIS J.G.L., REID W.G.J., O'SULLIVAN D.J., WILLIAMSON P.M., VC (1994). The Sydney multicentre study of Parkinson's disease : a randomised, prospective five years study comparing low dose bromocriptine with low dose levodopacarbidopa. J Neurol Neurosurg Psychiatry, 57: 903-910.
18. HORSTINK M.W.I.M., ZlJLMANS J.C.M., PASMAN J.W., BERGER H.J.C., VAN'T HOF M.A. (1990). Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry, 53:224-226.
19. JENNER P. (1995). The rationale for the use of dopamine agonists in Parkinson's disease. Neurology, 45 (suppl3) : S6-S12.
20. JENNER P. (1997). Mechanisms of motor complications in Parkinson's disease - a discussion. In : "Beyong the decade of the brain - vol 2 : dopamine agonists in early Parkinson's disease", ed : Olanow W., Obeso J. Wells Medical Limited, Royal Tunbridge Wells, pp 131-140.
21. JENNER P., TULLOCH I. (1997). The preclinical pharmacology of ropinirole-receptor interactions, antiparkinsonian activity and potential to induce dyskinesia. In : "Beyong the decade of the brain - vol 2 : dopamine agonists in early Parkinson's disease", ed : Olanow W., Obeso J. Wells Medical Limited, Royal Tunbridge Wells, pp 115-128.
22. JUNCOS J.L., ENGBER T.M., RAISMAN R., CHASE T.N. (1989). Continuous and intermittent levodopa differentially affect basal " ganglia function. Ann Neurol, 25:473-478.
23. KORCZYN A., BROOKS D., BRUNT E., POEWE W., RASCOL O., STOCCHI F., on the behalf of the 053 study group. (1998). Ropinirole versus bromocriptine in the treatment of Parkinson's disease : a 6 month interim report of a 3 year study. Mov Disorders (in press).
24. KOSTIC V., PRZEDBORSKI S., FLASTER E., STERNIC N. (1991). Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology, 41:202-205.
25. KURLAN R. (1988). International symposium on early dopamine agonist therapy of Parkinson's disease. Arch Neurol, 45:204-208.
26. LANGSTON W.J., BALLARD P. (1984). Parkinsonism induced by MPTP : implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sei, 11:160-165.
27. LEES A.J., STERN G.M. (1981). Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry, 44:1020-1023.
28. LUQUIN M.R., LACUNA J., OBESO J.A. (1992). Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann Neurol, 31: 551-554.
29. MARKHAM C.H., DIAMOND S.G. (1986). Long-term follow-up of early dopa treatment in Parkinson's disease. Ann Neurol 19 : 365-372.
30. MELAMED E. (1986). Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. Arch Neurol, 43: 402-405.
31. MONES R.J. (1973). Experimental dyskinesias in normal rhesus monkey. Adv Neurol, 1: 665-669.
32. MONTASTRUC J.L., RASCAL O., RASCOL A. (1989). A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients : a 3 year follow-up. J Neurol Neurosurg Psychiatry, 52: 773-775.
33. MONTASTRUC J.L., RASCOL O., SENARD J.M. (1993). Current status of dopamine agonists in Parkinson's disease management. Drugs, 46:384-393.
34. MONTASTRUC J.L., RASCOL O., SENARD J.M., RASCOL A. (1994). A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease : a five year follow up. J Neurol Neurosurg Psychiatry, 57:1034-1038.
35. Nurr J.G. (1990). Levodopa-induced dyskinesia : review, observations, and speculations. Neurology, 40:340-345.
36. PARKINSON STUDY GROUP. (1996). Impact of deprenyl and tocopherol treatment on Parkinson's disease in DAT ATOP patients requiring levodopa. Ann Neurol, 39: 37-45.
37. PARKINSON STUDY GROUP. Safety and efficacy of Pramipexole in early Parkinson Disease (1997). A randomized dose-ranging study. JAMA, 278:125-130.
38. PARKINSON'S DISEASE RESEARCH GROUP IN THE UNITED KINGDOM. (1993). Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease : three year interim report. Brit Med J, 307:469-472.
39. PICCINI P., WEEKS R.A., BROOKS D.J. (1997). Alterations in opioid receptor binding in Parkinson's disease patients with levodopainduced dyskinesias. Ann Neurol, 42: 720-726.
40. RAJPUT A.H., MARTIN W., SAINT-HILAIRE M.H., DORFLINGER E., PEDDER S. (1997). Tolcapone improves motor function in parkinsonian patients with the "wearing-off phenomenon : a double-blind, placebo-controlled, multicenter trial. Neurology, 49:1066-1071.
41. RASCOL A., GUIRAUD B., MONTASTRUC J.L., DAVID J., CLANET M. (1979). Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry, 42:143-150.
42. RASCOL A., MONTASTRUC J.L., RASCOL O. (1984). Should dopamine agonists be given early or late in the treatment of Parkinson's disease ? Can J Neurol Sei, 11 (1 suppl) : 229-232.
43. RASCOL O. (1997). Ropinirole : a clinical profile. In : "Beyong the decade of the brain, vol 2, dopamine agonists in early Parkinson's disease', ed : Olanow W., Obeso J. Wells Medical Limited, Royal Tunbridge Wells, 163-175.
44. RASCOL O., BLIN O., SOUBROUILLARD C., FABRE N., VIALLET F., THALAMAS C., AZULAY J.P., LAFNITZEGGER K., WRIGHT S., Murr J. (1997). ABT-431, a selective D1 agonist has efficacy in patients with Parkinson's disease. Neurology, 48: 269-270.
45. RASCOL O., BROOKS D., BRUNT E., KORCZYN A., POEWE W., STOCCHI F. on behalf of the 056 study group (1998). Ropinirole in the treatment of early Parkinson's disease : a 6-month interim report of a 5 year L-dopa controlled study. Mov Disorders (in press).
46. RINNE U.K. (1987). Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease : a 5 year follow-up. Neurology, 37: 826-828.
47. RINNE U.K., BRACCO F., CHOUZA C., DUPONT E., GERSHANIK O., MARTI MASSO J.F., MONTASTRUC J.L., MARSDEN C.D., DUBINI A., ORLANDO N., GRIMALDI R., AND THE PKDS009 COLLABORATIVE STUDY GROUP. (1997). Cabergoline in the treatment of early Parkinson's disease : results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology, 48:363-368.
48. ROSENBERG W.M.C., SACKETT D.L. (1996). On the need for evidence - based medicine. Therapie, 51:212-217.
49. SASSIN F.J., TAUB S., WEITZMAN E.D. (1972). Hyperkinesia and changes in behavior produced in normal monkeys by L-dopa. Neurology, 22:1122-1125.
50. TUFUANSKI N., LEES A.J., BROOKS D.J. (1997). In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology, 49:717-723.